Epizyme’s Tazemetostat Gains US FDA Panel Nod For Accelerated Approval In Epithelioid Sarcoma

 
• By Sue Sutter
  
FDA Advisory Committee Feature image
Oncologic Drugs Advisory Committee voted unanimously that tazemetostat's benefits outweigh its risks.

More from US FDA Performance Tracker

More from Regulatory Trackers